Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion

Kidney International

Volumn 70, Issue 4, 2006, Pages 647-653

  Shearer, G C ^a,b   Kaysen, G A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hyperlipidemia; Lipoprotein; Proteinuria; Triglycerides

Indexed keywords

HEPARIN; IODINE 125; LIPOPROTEIN LIPASE; MESSENGER RNA; SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; BINDING AFFINITY; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME BINDING; ENZYME RELEASE; GENE EXPRESSION; HEART MUSCLE; HEART PERFUSION; HYPOALBUMINEMIA; ISOLATED HEART; MALE; NEPHROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 33747032269     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000318     Document Type: Article

References (40)

1. Warwick GL, Caslake MJ, Boulton-Jones JM et al. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990; 39: 187-192.
2. Staprans I, Felts JM, Couser WG. Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats. Metabolism 1987; 36: 496-501.
3. Marsh JB. Lipoprotein metabolism in experimental nephrosis. J Lipid Res 1984; 25: 1619-1623.
4. Shafrir E, Brenner T. Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis. I: Studies in rat in vivo. Lipids 1979; 14: 695-702.
5. Brenner T, Shafrir E. Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis: II. Perfused rat liver. Lipids 1980; 15: 637-643.
6. Garber DW, Gottlieb BA, Marsh JB, Sparks CE. Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 1984; 74: 1375-1383.
7. Levy E, Ziv E, Bar-On H, Shafrir E. Experimental nephrotic syndrome: removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin. Biochim Biophys Acta 1990; 1043: 259-266.
8. Kaysen GA, Mehendru L, Pan XM, Staprans I. Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis. Am J Physiol 1992; 263: F335-F341.
9. Kaysen GA, Pan XM, Couser WG, Staprans I. Defective lipolysis persists in hearts of rats with heymann nephritis in the absence of nephrotic plasma. Am J Kidney Dis 1993; 22: 128-134.
10. Shearer GC, Kaysen GA. Proteinuria and plasma compositional changes contribute to defective lipoprotein catabolism in the nephrotic syndrome by separate mechanisms. Am J Kidney Dis 2001; 37: S119-S122.
11. Shearer GC, Couser WG, Kaysen GA. Nephrotic livers secrete normal VLDL that acquire structural and functional defects following interaction with HDL. Kidney Int 2004; 65: 228-237.
12. Yoshino G, Hirano T, Nagata K et al. Hypertriglyceridemia in nephrotic rats is due to a clearance defect of plasma triglyceride: overproduction of triglyceride-rich lipoprotein is not an obligatory factor. J Lipid Res 1993; 34: 875-884.
13. Camps L, Reina M, Llobera M et al. Lipoprotein lipase: cellular origin and functional distribution. Am J Physiol 1990; 258: C673-C681.
14. Semb H, Olivecrona T. The relation between glycosylation and activity of guinea pig lipoprotein lipase. J Biol Chem 1989; 264: 4195-4200.
15. Pillarisetti S, Paka L, Sasaki A et al. Endothelial cell heparanase modulation of lipoprotein lipase activity. Evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem 1997; 272: 15753-15759.
16. Davies RW, Staprans I, Hutchison FN, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990; 86: 600-605.
17. Shafrir E. Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome - modulation by glucocorticoids and triiodothyronine. Isr J Med Sci 1996; 32: 390-397.
18. Hirano T, Ebara T, Furukawa S et al. Mechanism of hypertriglyceridemia in Dahl salt-sensitive rats, an animal model of spontaneous nephrotic syndrome. Metabolism 1994; 43: 248-256.
19. Samuelsson O, Attman PO, Knight-Gibson C et al. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Nephron 1997; 75: 286-294.
20. Kaysen GA, Sun X, Jones Jr H et al. Non-iron mediated alteration in hepatic transferrin gene expression in the nephrotic rat. Kidney Int 1995; 47: 1068-1077.
21. Stevenson FT, Greene S, Kaysen GA. Serum alpha 2-macroglobulin and alpha 1-inhibitor 3 concentrations are increased in hypoalbuminemia by post-transcriptional mechanisms. Kidney Int 1998; 53: 67-75.
22. Kang J, Holland M, Jones H, Kaysen GA. Coordinate augmentation in expression of genes encoding transcription factors and liver secretory proteins in hypo-oncotic states. Kidney Int 1999; 56: 452-460.
23. Sun X, Jones Jr H, Joles JA et al. Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am J Physiol 1992; 262: F755-F761.
24. Bagby GJ. Heparin-independent release of lipoprotein lipase activity from perfused rat hearts. Biochim Biophys Acta 1983; 753: 47-52.
25. Cupp M, Bensadoun A, Melford K. Heparin decreases the degradation rate of lipoprotein lipase in adipocytes. J Biol Chem 1987; 262: 6383-6388.
26. Liang K, Vaziri ND. Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 1997; 130: 387-394.
27. Raats CJ, van den Born J, Bakker MA et al. Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 2000; 156: 1749-1765.
28. Sorensson J, Bjornson A, Ohlson M et al. Synthesis of sulfated proteoglycans by bovine glomerular endothelial cells in culture. Am J Physiol Renal Physiol 2003; 284: F373-F380.
29. Yang Y, Zhang SY, Sich M et al. Glomerular extracellular matrix and growth factors in diffuse mesangial sclerosis. Pediatr Nephrol 2001; 16: 429-438.
30. Pang L, Sivaram P, Goldberg IJ. Cell-surface expression of an amino-terminal fragment of apolipoprotein B increases lipoprotein lipase binding to cells. J Biol Chem 1996; 271: 19518-19523.
31. Sasaki A, Goldberg IJ. Lipoprotein lipase release from BFC-1 beta adipocytes. Effects of triglyceride-rich lipoproteins and lipolysis products. J Biol Chem 1992; 267: 15198-15204.
32. Joles JA, Willekes-Koolschijn N, Koomans HA. Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine. Kidney Int 1997; 52: 761-770.
33. Joles JA, Willekes-Koolschijn N, Scheek LM et al. Lipoprotein phospholipid composition and LCAT activity in nephrotic and analbuminemic rats. Kidney Int 1994; 46: 97-104.
34. Obunike JC, Pillarisetti S, Paka L et al. The heparin-binding proteins apolipoprotein E and lipoprotein lipase enhance cellular proteoglycan production. Arterioscler Thromb Vasc Biol 2000; 20: 111-118.
35. Shearer GC, Newman JW, Hammock BD, Kaysen GA. Graded effects of proteinuria on HDL structure in nephrotic rats. J Am Soc Nephrol 2005; 16: 1309-1319.
36. Liu L, Severson DL. Endothelial binding sites for lipoprotein lipase are not diminished in perfused hearts from diabetic rats. Can J Physiol Pharmacol 1996; 74: 1204-1209.
37. Krauss RM, Levy RI, Fredrickson DS. Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia. J Clin Invest 1974; 54: 1107-1124.
38. Chajek-Shaul T, Bengtsson-Olivecrona G, Peterson J, Olivecrona T. Metabolic fate of rat heart endothelial lipoprotein lipase. Am J Physiol 1988; 255: E247-E254.
39. McGuire PG, Orkin RW. Isolation of rat aortic endothelial cells by primary explant techniques and their phenotypic modulation by defined substrata. Lab Invest 1987; 57: 94-105.
40. Helmkamp RW, Contreras MA, Bale WF. I-131-labeling of proteins by the iodine monochloride method. Int J Appl Radiat Isot 1967; 18: 737-746.